Bill > SB1555

This bill addresses the potential rescheduling of crystalline polymorph psilocybin, a specific form of psilocybin, if it receives approval from the United States Food and Drug Administration (FDA) and is rescheduled by the United States Drug Enforcement Administration (DEA). Currently, psilocybin is a Schedule I controlled substance, which means it is not recognized as having medical use. The bill would allow this specific pharmaceutical composition of psilocybin to be prescribed in Arizona if it is approved by the FDA and moved to a schedule other than Schedule I by the DEA. The legislation includes a sunset provision, which means these changes will only take effect if psilocybin receives FDA approval as a prescription medication by January 1, 2031, and is controlled under a federal interim final rule. The legislative intent is to ensure rapid patient access to this treatment option if and when it becomes federally approved. The Arizona State Board of Pharmacy is required to notify the legislative council by February 1, 2031, whether the conditions for implementation have been met, essentially creating a mechanism to track and implement these potential future changes to controlled substance regulations.

Health and Social Services

https://apps.azleg.gov/BillStatus/BillOverview/82993